The company develops novel immunomodulators that target key pathways of the immune response, improving outcomes for serious, unmet medical conditions in the critical care setting. Its lead product is being developed to treat a rare, life-threatening infection with high morbidity and mortality, showing meaningful improvement across multiple endpoints. This enables healthcare institutions to significantly improve the hosts' ability to fight the infection and reduce tissue damage caused during acute inflammatory situations. Founded in 2003 and based in HaMerkaz, Israel, Atox Bio is focused on improving outcomes for patients with infectious and inflammatory diseases as well as ischemia/reperfusion injuries.